Login / Signup

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

Juan Pablo FriasMichael A NauckJoanna VanCharles BensonRoss BrayXuewei CuiZvonko MilicevicShweta UrvaAxel HauptDeborah A Robins
Published in: Diabetes, obesity & metabolism (2020)
Tirzepatide treatment for 12 weeks resulted in clinically significant reductions in HbA1c. This suggests that lower starting doses and smaller dose increments are associated with a more favourable side effect profile.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • open label
  • phase iii
  • phase ii
  • study protocol
  • blood pressure
  • combination therapy
  • replacement therapy
  • type diabetes
  • insulin resistance
  • preterm birth